Please Wait...

Expert Biomarker Services For Alzheimer's Disease Research

Alzheimer's Disease (AD), a fatal neurodegenerative disorder characterized by progressive cognitive impairment and memory loss, is the major cause of dementia. The two main neuropathological hallmarks of AD are extracellular amyloid plaques, and neurofibrillary tangles (NTFs), primarily composed of the protein tau.

A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a normal or pathological process, or as a measure of response to therapy. Application of cerebrospinal fluid-based (CSF) and blood-based biomarkers in clinical research has revolutionized the understanding of AD. Especially, detection of Aβ and tau in CSF has led to crucial advancements in disease detection at its earliest stage (Fig 1).

In general, biomarkers have proven extremely useful throughout the different steps of AD clinical trials: patient inclusion and enrichment, and evaluation of target engagement and clinical efficacy of therapeutic drugs. Changes in CSF and blood-based biomarkers reflect different pathological processes in AD.

Informed Decision-Making. Quality Data. Improved Outcomes.

Bioclinica AD biochemical marker capabilities:

  • Fit-for-Purpose Validation
  • Expertise in Sample Handling
  • Centralized analysis to minimize assay variability
  • Controlled storage of biological samples
  • Established partnership with internationally recognized KOL
  • AD specific Proficiency Testing Program

 

Fluid-based biomarkers can facilitate development of new AD therapies by allowing:

  • Enrichment and stratification of patients
  • Evaluation of target engagment
  • Measurement of disease progression
  • Clinical efficacy and safety assessment of therapeutic drugs

 

Download our AD Biomarker Expertise Sheet

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

On the hunt for agile IRT? Ask these 5 Qs to see if it's the real thing. DISCLOSURE: We happen to have such an offe… https://t.co/S6507WxBC8
bioclinica (Yesterday)
Be among the 1st to hear findings presented in 6 scientific posters in which experts @bioclinica in #Alzheimers… https://t.co/4mBEtFiX0a
bioclinica (3 days ago)
Still using manual methods for trial budget management and forecasting ? A Bioclinica whitepaper shows how purpose-… https://t.co/WlrHLk9B0z
bioclinica (4 days ago)
Swing by @Bioclinica to discuss global site network partnering opportunities during @MySCRS Asia-Pac Site Solutions… https://t.co/m8GHxSmPMY
bioclinica (5 days ago)
Hello from Clinical Operations in Oncology Trials East Coast where Bioclinica is exhibiting & presenting a case stu… https://t.co/oTKJAVddH4
bioclinica (2 weeks ago)
Challenge overcome! Course-correct a clinical trial & collect 400 time points from 40 sites across the US & EU -- a… https://t.co/n3TLrjW3xi
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen